Oxaliplatin-Based Versus Alkylating Agent in Neuroendocrine Tumors According to the O6-Methylguanine-DNA Methyltransferase Status: A Randomized Phase II Study (MGMT-NET) The median time post-HCT was ...
The American Journal of Preventive Cardiology (AJPC) announces the publication of the POLY-ACS trial investigating the effectiveness of a polypill strategy, combining multiple evidence-based therapies ...
Idiopathic normal-pressure hydrocephalus is a neurologic disorder characterized by impaired gait, balance, cognition, and bladder control in older adults. The disorder is treated with shunt surgery, ...
Contrary to existing evidence from observational studies, the meningococcal B vaccine (4CMenB) has no effect on preventing ...
OPERETTA: A phase II study evaluating neoadjuvant and adjuvant olaparib plus pembrolizumab following platinum-based chemotherapy plus pembrolizumab for germline BRCA mutated triple negative breast ...
MADRID, Aug. 31, 2025 /PRNewswire/ --Johnson & Johnson (NYSE: JNJ) – Late breaking clinical science data, presented at the European Society of Cardiology (ESC) Congress today and simultaneously ...
Thought LeadersAoife Hayes, Kevin O'Regan & Julie ScanlonClinical Trials Assitant, Operations Manager & Quality Assurance ManagerAtlantia Clinical Trials Food clinical trials may not be as familiar to ...
Hosted on MSN
Clinical trial shows taking blood pressure medication at night improves nocturnal and daytime control
Research led by Sichuan University in China has revealed that bedtime antihypertensive medication dosing improves nocturnal blood pressure control over morning dosing in patients with hypertension.
In a multicenter, randomized, crossover trial involving children 1 to 7 years of age with type 1 diabetes, a closed-loop system was compared with sensor-augmented pump therapy in random order. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results